
## Andrew T Stefka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6057075/publications.pdf Version: 2024-02-01



| # | Article  | IF  | CITATIONS |
|---|--|-----|-----------|
| 1 | Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in<br>a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.<br>Blood Cancer Journal, 2021, 11, 19.              | 6.2 | 40        |
| 2 | Potent antiâ€myeloma activity of the TOPK inhibitor OTS514 in preâ€clinical models. Cancer Medicine, 2020,<br>9, 324-334.  | 2.8 | 14        |
| 3 | Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.<br>Blood, 2020, 136, 2513-2523.  | 1.4 | 56        |
| 4 | Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next<br>generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of<br>KRd+ASCT Journal of Clinical Oncology, 2020, 38, 8513-8513. | 1.6 | 5         |
| 5 | Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN),<br>and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed<br>Multiple Myeloma (NDMM). Blood, 2016, 128, 675-675.      | 1.4 | 38        |